Zucara Therapeutics Inc. news
Toronto, Canada, July 27, 2021 – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has dosed the first patients in its Phase 1b trial of ZT-01.
“We are excited to advance ZT-01 to the next stage of development after our recent successful completion of a Phase 1 safety and pharmacokinetics study,” said Richard Liggins, Zucara
Toronto, Canada, May 26, 2021 – Zucara Therapeutics Inc. (“Zucara” or the “Company”), a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has successfully completed a Phase 1 study evaluating single and multiple ascending doses of ZT-01.
“We are pleased with the results of the Phase 1 trial, which demonstrated that ZT-01 was safe and
Toronto, Canada, November 2, 2020 – Zucara Therapeutics Inc. (“Zucara” or the “Company”), a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has expanded the development of ZT-01, a somatostatin receptor 2 antagonist (“SSTR2a”), to Type 2 Diabetes (“T2D”).
The development of ZT-01 for T2D will be supported, in part,
Zucara Therapeutics Inc. (“Zucara” or the “Company”), a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has expanded the development of ZT-01, a somatostatin receptor 2 antagonist (“SSTR2a”), to Type 2 Diabetes (“T2D”).
The development of ZT-01 for T2D will be supported, in part, by advisory services and up to $415,000 i
Toronto, Canada, September 29, 2020 – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has dosed the first subject in its Phase 1 trial of ZT-01.
“Initiation of our Phase 1 study of ZT-01, which has been our goal since establishing the Company in 2014, is a monumental milestone for Zucara,” said Michael Midmer, Zucara Thera